Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
CA 2351865 A1 · Owner: Grugni, Mario · Inventors: Farina, Carlo; Raveglia, Luca Francesco; Giardina, Giuseppe
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound, or a solvate or a salt thereof of formula (I): wherein, Ar is an , optionally substituted aryl or a C5-7 cycloalkdienyl group or an optionally , substituted C5-7 cycloalkyl group or an optionally substituted single or fused ring aromatic heterocyclic group; R is hydrogen linear or branched C1-6 , alkyl, C3-7 cycloalkyl C3-7 cycloalkylalkyl, R1 represents hydrogen or up to three optional substituents selected from the list consisting of: C1-6 alkyl C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy halogen, nitro, cyano, carboxy, carboxamido sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl acyloxy, amino or mono- and di-C1-6 alkylamino; R2 represents a moiety -(CH2)n-NY1Y2 wherein n …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 19, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 19, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 19, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.